Iovance Biotherapeutics upgraded by Piper Sandler with a new price target

1/27/23 7:17:23 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Piper Sandler upgraded Iovance Biotherapeutics from Neutral to Overweight and set a new price target of $14.00 from $11.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IOVA

Date	Price Target	Rating	Analyst
5/16/2025	$2.00	Buy → Neutral	UBS
5/12/2025		Buy → Hold	Truist
5/9/2025		Mkt Outperform → Mkt Perform	Citizens JMP
10/24/2024	$17.00	Buy	UBS
7/29/2024	$19.00 → $10.00	Overweight → Neutral	Piper Sandler
11/20/2023	$12.00	Buy	Goldman
9/18/2023	$40.00 → $18.00	Overweight	Barclays
5/30/2023	$11.00 → $17.00	Equal Weight → Overweight	Wells Fargo